MOESM3 of Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis
收藏数据链接：
官方服务：
资源简介：
Additional file 3: Figure S1. Study Design With Dosing Schedule and Patient Disposition. (A) Schematic representation of the MR and SR OLE study designs and dose-titration schedules. All patients in the OLE (including those previously on placebo) received gantenerumab subcutaneously every 4 weeks. Dose-titration schedules for uptitration to 1200 mg were assigned based on APOEε4 carrier status and last treatment dose during the double-blind phase. (B) Patient disposition. a Including 1 patient who missed their week 52 visit.
提供机构：
Guoqiao Wang创建时间：
2019-12-13
